SCHEMBL524457

SCHEMBL524457

COC(=O)c1cccc(C)c1C

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.53
TSHR P16473 1/20 0.53
NR4A2 P43354 1/20 0.53
ALDH1A1 P00352 4/20 0.52
CFTR P13569 1/20 0.52
HSD17B10 Q99714 1/20 0.52
POLB P06746 2/20 0.50
KDM4E B2RXH2 2/20 0.50
ATM Q13315 1/20 0.50
FFAR4 Q5NUL3 1/20 0.50
KMT2A Q03164 4/20 0.49
MEN1 O00255 2/20 0.49
MYC P01106 1/20 0.49
MAPT P10636 3/20 0.47
RAB9A P51151 2/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
AKR1B10 O60218 1/20 0.47
TRPA1 O75762 1/20 0.47
ABCB11 O95342 1/20 0.47
DHFR P00374 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3511612 0.89 LMNA (0.59) LMNATSHRNR4A2ALDH1A1CFTR
SCHEMBL30341822 0.86 KMT2A (0.55) LMNATSHRNR4A2ALDH1A1CFTR
SCHEMBL6113326 0.85 MEN1 (0.50) LMNATSHRALDH1A1HSD17B10POLB
SCHEMBL32667968 0.85 MEN1 (0.50) LMNATSHRALDH1A1HSD17B10POLB
SCHEMBL126498 0.85 MEN1 (0.50) LMNATSHRALDH1A1HSD17B10POLB
SCHEMBL27301503 0.84 MEN1 (0.47) LMNATSHRNR4A2ALDH1A1HSD17B10
SCHEMBL2898209 0.83 MYC (0.54) LMNATSHRNR4A2ALDH1A1CFTR
SCHEMBL9157077 0.83 KMT2A (0.49) LMNATSHRALDH1A1HSD17B10POLB
SCHEMBL29634134 0.83 TSHR (0.53) LMNATSHRALDH1A1CFTRHSD17B10
SCHEMBL19849652 0.83 TSHR (0.53) LMNATSHRALDH1A1CFTRHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 160 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118240886-A Method for synthesizing ethyl salicylate compound by biological enzyme catalysis 济南大学 2024-06-25 CN claimed
CN-102791695-B Cyclopentyl-and cycloheptylpyrazoles as FXR modulators 霍夫曼-拉罗奇有限公司 2016-08-24 CN claimed
JP-2008500943-A 2008-01-17 JP claimed
EP-1622717-A2 AFFINITY-BASED ENRICHMENT OF PHOSPHORYLATED PEPTIDES AND/OR PROTEINS ProteoSys AG (DE) 2006-02-08 EP claimed
WO-2004099233-A2 AFFINITY-BASED ENRICHMENT OF PHOSPHORYLATED PEPTIDES AND/OR PROTEINS PROTEOSYS AG (DE) 2004-11-18 WO claimed
EP-4700024-A1 CYCLOPENTYLPYRAZOLAMINE DERIVATIVE AND USE THEREOF Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) 2026-02-25 EP disclosed
US-20240383884-A1 COMPOUNDS AND METHODS FOR MODULATING INTERLEUKIN-2-INDUCIBLE T-CELL KINASE CORVUS PHARMACEUTICALS, INC. 2024-11-21 US disclosed
WO-2024217431-A1 CYCLOPENTYLPYRAZOLAMINE DERIVATIVE AND USE THEREOF 正大天晴药业集团股份有限公司 2024-10-24 WO disclosed
US-20240216355-A1 PHARMACEUTICAL COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF A DISEASE OR DISORDER CAUSED BY OR ASSOCIATED WITH ONE OR MORE PREMATURE TERMINATION CODONS MONTE ROSA THERAPEUTICS AG (CH) 2024-07-04 US disclosed
CN-118240886-A Method for synthesizing ethyl salicylate compound by biological enzyme catalysis 济南大学 2024-06-25 CN disclosed
CN-117510360-B Continuous preparation method, device and product of 2-amino-5-chloro- (N, 3) -dimethylbenzamide 天津凯莱英医药科技发展有限公司 2024-04-12 CN disclosed
US-11897874-B2 Compounds and methods for modulating Interleukin-2-inducible T-cell kinase CORVUS PHARMACEUTICALS, INC. (US) 2024-02-13 US disclosed
US-20050288340-A1 Substituted heteroaryl- and phenylsulfamoyl compounds PFIZER INC 2005-12-29 US disclosed
WO-2004099233-A2 AFFINITY-BASED ENRICHMENT OF PHOSPHORYLATED PEPTIDES AND/OR PROTEINS PROTEOSYS AG (DE) 2004-11-18 WO disclosed
US-20030225091-A1 Dual inhibitors of adipocyte fatty acid binding protein and keratinocyte fatty acid binding protein BRISTOL-MYERS SQUIBB COMPANY 2003-12-04 US disclosed
US-5026856-A Bactericides WAKUNAGA SEIYAKU KABUSHIKI KAISHA (JP) 1991-06-25 US disclosed
EP-0343560-A2 Isoindoline derivative WAKUNAGA SEIYAKU KABUSHIKI KAISHA (JP) 1989-11-29 EP disclosed
US-4699698-A Preparation of benzoic acid ortho-esters and novel compounds of this type BASF AKTIENGESELLSCHAFT (DE) 1987-10-13 US disclosed
US-4355173-A Process for the preparation of alkyl carboxylate MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) 1982-10-19 US disclosed
US-3983159-A Process for producing biphenylpolycarboxylic acid ester TEIJIN LIMITED (JA) 1976-09-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050288340-A1 Substituted heteroaryl- and phenylsulfamoyl compounds PPARA, PPARG, PPARD LMNA 319/4885TSHR 400/4885NR4A2 54/4885
US-20030225091-A1 Dual inhibitors of adipocyte fatty acid binding protein and keratinocyte fatty acid binding protein FABP4, FABP2, FABP1 LMNA 2337/4885TSHR 2835/4885NR4A2 341/4885
US-20240216355-A1 PHARMACEUTICAL COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF A DISEASE OR DISORDER CAUSED BY OR ASSOCIATED WITH ONE OR MORE PREMATURE TERMINATION CODONS UPF1, NSUN2, RTF2 LMNA 395/4885TSHR 1410/4885NR4A2 2656/4885
US-20240383884-A1 COMPOUNDS AND METHODS FOR MODULATING INTERLEUKIN-2-INDUCIBLE T-CELL KINASE IL2, NFATC1, IL2RA LMNA 4243/4885TSHR 4016/4885NR4A2 1862/4885
US-11897874-B2 Compounds and methods for modulating Interleukin-2-inducible T-cell kinase IL2, NFATC1, IL2RA LMNA 4243/4885TSHR 4016/4885NR4A2 1862/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.